Affimed reports acceptance of abstract on AFM28 preclinical data at EHA 2024

Affimed N.V. announced the publication of an abstract for the annual congress of the European Hematology Association, taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed’s CD16A/CD123-targeting ICE, AFM28, in an acute myeloid leukemia mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls. In addition, the abstract shows a data set from a collaboration with Dr. Hind Medyouf’s group at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. In a newly engineered ex vivo Human Organotypic Marrow Environment model, the combination of AFM28 and allogeneic NK cells can lead to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells. Importantly, the HOME model exhibits key immune suppressive cellular components, i.e. mesenchymal niche cells, enhancing the translational relevance of AFM28 preclinical activity. “The significant anti-leukemic activity of AFM28 observed in in vivo as well as in vitro settings is encouraging,” said Dr. Wolfgang Fischer, COO of Affimed. “In combination with the previously demonstrated safety profile in cynomolgus monkeys, these data indicate AFM28’s potential to eradicate residual disease in patients with AML in an effective and safe manner.”